Vertex Pharmaceuticals, Inc.

Neurocrine Biosciences, Inc.

Boehringer Ingelheim International Gmbh

Timothy Richard Coon

Mark Thomas Miller

Jinglan Zhou

Jeremy J Clemens

Bryan A Frieman

Jason McCartney

Corey Don Anderson

Sara Sabina Hadida Ruah

Neil Ashweek

Yun-Fei Zhu

Peter Grootenhuis

Andreas Peter Termin

Peter Diederik Jan Grootenhuis

Brian Richard Bear

Fredrick Van Goor

Thomas Cleveland

Martin W Rowbottom

Warren Stanfield Wade

Mi Chen

Todd Ewing

Prasuna Paraselli

Haripada Khatuya

Johnny Uy

Fabrice Pierre

Richard B Lowe

Paul Krenitsky

Alina Silina

Vijayalaksmi Arumugam

Hayley Marie Binch

Pramod Virupax Joshi

Gulin Erdogan Marelius

Sara Sabina Hadida-Ruah

Benjamin Joseph Littler

John E Cochran

Beili Zhang

Michel Gallant

Claudio F Sturino

Ales Medek

David Andrew Siesel

Brett C Bookser

Yi Shi

Thumkunta Jagadeeswar Reddy

Brett Bradley Busch

Weichao George Chen

Yeeman K Ramtohul

Chen Chen

Brian Dyck

Junko Tamiya

Troy Vickers

Lino J Valdez

Graham Beaton

Wanlong Jiang

Willy Moree

Liren Zhao

Sara E Swift

Nicole Smith

Vito Melillo

Fabrice Jean Denis Pierre

Raymond Stanley Gross

Erica Lynn Conroy

Chun-Chieh Lin

Georgia McGaughey Nicholls

Jinghua Yu

Paul Angell

Michael Waldo

Kevin Gagnon

Muna Shrestha

Alexander Russell Abela

Minson Baek

Armando Urbina

Carl Zwicker

Senait G Ghirmai

Anton V Gulevich

Clara Kuang-Ju Hsia

Ping Kang

Florence Jovic

Carl V Vogel

Jennifer Lu

Jicong Li

William Schulz Bechara

Julie Laterreur

Nicole Harriott

Joe Anh Tran

Brian J Hare

Wilna (Willy) J Moree

Paul John Krenitsky

David M Altshuler

Lino Valdez

Reshma Kewalramani

Patrick R Sosnay

Jason Mccartney

Claudio Sturino

Bartlomiej Borek

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

Modulators of cystic fibrosis transmembrane conductance regulator

Crystalline forms of Compound I: pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Crystalline forms of CFTR modulators

The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

Process of making CFTR modulators

Compounds of Formula (I): pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof. 

Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulators

The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R, R, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof. 

Growing community of inventors

Carlsbad, CA, United States of America

Timothy Richard Coon